News

Myriad Genetics Expands MyRisk Test with 15 New Genes for Cancer Care

Myriad Genetics Expands MyRisk Test with 15 New Genes for Cancer Care

Myriad Genetics Enhances MyRisk Test with Expanded Gene Panel

Myriad Genetics, Inc. (NASDAQ: MYGN), a notable leader in molecular diagnostics and precision medicine, has made an exciting advancement by adding 15 clinically actionable genes to its MyRisk® Hereditary Cancer Test. This enhancement reflects a strong commitment to addressing the evolving clinical needs of healthcare providers and patients alike.

New Genes in the MyRisk Panel

The MyRisk Test, known for being a premier gold standard in germline testing, has now expanded its gene coverage significantly. This update aligns with several authoritative guidelines, including those from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). The new additions bring the total number of genes analyzed in the MyRisk panel to 63, which spans over 11 distinct cancer types.

Importance of Gene Actionability

These newly incorporated genes are not only relevant but are strongly linked with cancer risk and clinical actionability. This means that their inclusion enhances the clinical insights available for patient care, ultimately leading to better treatment outcomes. Each carefully selected gene offers meaningful information that can guide health professionals in making informed treatment decisions for patients.

Commitment to Patient Care

Dr. Dale Muzzey, Chief Scientific Officer at Myriad Genetics, emphasized the company's dedication to elevating patient care by stating, “While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels.” This focus on actionable insights underlines the importance of testing for genes that influence treatment decisions, reinforcing the core mission of Myriad with the MyRisk Test.

How the MyRisk Test Works

The MyRisk Test is strategically designed to offer clinical value throughout the entire cancer care continuum. It assists healthcare providers in making treatment choices, planning surveillance strategies, and assessing family risk across various types of cancer. The convenience of ordering and reviewing MyRisk Test results can be done directly through paper requisition forms, the Myriad patient portal, and compatibility with several electronic medical record systems, including EPIC and OncoEMR.

Future of Genetic Testing

As advancements continue to emerge in the field of genetic testing, Myriad Genetics remains steadfast in its commitment to adapt and expand its offerings. By staying at the forefront of clinical guidelines and seeking to improve patient outcomes, Myriad positions itself as a leader in precision medicine, enhancing the capabilities of healthcare professionals in delivering quality patient care.

Accessing Gene Management Information

Healthcare providers and interested parties can access the complete list of genes and the related medical management recommendations through the Myriad gene table. This resource serves as a vital tool for understanding the implications of the new genes added to the MyRisk Test.

About Myriad Genetics

Myriad Genetics is an innovative company dedicated to advancing the science of molecular diagnostic testing and precision medicine. It helps patients and healthcare providers by offering molecular tests that evaluate the risk of disease development and progress. Myriad’s focus on improving healthcare delivery and reducing costs makes it a pivotal player in the field.

Frequently Asked Questions

What is the MyRisk Test?

The MyRisk Test is a hereditary cancer test developed by Myriad Genetics that evaluates genetic risk for various cancers.

What new genes were added to the MyRisk Test?

Fifteen new clinically actionable genes related to cancer risk have been added to enhance the insights provided by the MyRisk Test.

How does this expansion benefit patient care?

The new genes included in the MyRisk Test offer healthcare providers clearer actionability and guidance for treatment decisions, ultimately improving patient outcomes.

Is the MyRisk Test easy for doctors to order?

Yes, healthcare professionals can order the MyRisk Test easily through multiple platforms including paper requisition forms and electronic medical records.

Where can I find more information about Myriad Genetics?

More information can be accessed through the Myriad Genetics official website, which provides details on their tests and services.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Decoy Wines Bolsters Emmy Partnership with Creative Grant

Updated Category News Views 7

Popping Corks for Creativity: Decoy's New Chapter Stepping outside the vines and into the artistic limelight, Decoy Wines is shaking up the status quo. Announcing the launch of the Pour to What's Possible Grant, the brand is throwing down $10,000 to back creatives itching to make waves in entertainment. Now, doesn't that stand out? The Grit Behind the Grapes: Decoy's...

Continue Reading
TETRA Technologies to Engage at Key Investor Events

Updated Category News Views 1

Revving Up for Major Investor Conferences All eyes are on TETRA Technologies Inc. (NYSE:TTI) as they gear up to make splashy appearances at not one, but two high-profile investor conferences in New York. It's setting the stage for some potentially juicy conversations about where TTI, a player with deep roots in energy services, is heading in this whirlwind of an industry....

Continue Reading
Scienjoy's Strategic Stake in Education: Bold Move?

Updated Category News Views 0

Testing the Waters with Education Stake Talk about mixing oil and water. Scienjoy Holding Corporation, those tech-savvy folks from China's live streaming circles, have set their sights on education with a hefty 29.9% stake in Leader Education Limited. For HK$102.69 million, that’s about US$13.1 million, they’re jumping into an industry with a different flavor....

Continue Reading
PLAY Palm Angels Launches at Pacsun with Avani Gregg

Updated Category News Views 2

Revamping Streetwear with PLAY Palm Angels and Pacsun In a move that's making waves from the fashion runways straight into the heart of youth culture, PLAY Palm Angels is swooping into Pacsun, and they’re not just strolling in—they’re parading with a 41-piece fashion collection. Not to mention, they've snagged Avani Gregg, a powerhouse cultural influencer, to strut...

Continue Reading
HIMS Faces Class Action: Investors Eye Leadership

Updated Category News Views 0

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

Continue Reading
Robo.ai Surpasses $180 Million in Q2 Revenue Surge

Updated Category News Views 7

Robo.ai's Financial Rocket Lift-off: Q2 Highlights Who would've thought a single acquisition could propel a company's revenue north of $180 million in just three months? Well, Robo.ai, with its recent grab of Quantum Core Capital (QC Capital), shattered that ceiling, showcasing what a savvy acquisition and a dash of tech wizardry can achieve. Strong Quarter, Stronger...

Continue Reading
McLean Launches Program to Foster AI Capability

Updated Category News Views 1

Driving AI Adoption: A Shift Towards Human-Centric Learning McLean & Company has dropped an initiative that’s like laying fresh tracks for AI inclusion in businesses. Dubbed the Human-Centric AI Program, it’s a wake-up call to organizations struggling to shift AI from a novelty to a natural part of operations. This isn’t just about fiddling with AI tools; it’s...

Continue Reading
Cost of Living Tops Financial Worries in 2026

Updated Category News Views 6

Financial Stress — The Silent Productivity Killer Down in the trenches of nine-to-five, it’s money that keeps stealing workers' peace of mind. The TELUS Mental Health Index shines a glaring spotlight on this, revealing that 58% of U.S. workers are most stressed by living costs. Now, that's a kicker when stacking it next to retirement or emergency savings. Those take...

Continue Reading
Kroger's Strategic Shift: Ibbotson's Bold New Charge

Updated Category News Views 0

Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...

Continue Reading
York Urged to Retire Research Macaques After Probe

Updated Category News Views 3

Undercover Investigation Shakes Up York University If you thought the world of research was all about sterile labs and the pursuit of knowledge, think again. The Jane Goodall Institute (JGI), famed for championing animal welfare, has urged York University to let go of nine long-suffering rhesus macaques. Turns out, these macaques weren't exactly living their best lives....

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Exciting Launch of Super Fog Burzt Lemonade

Updated Category News Views 150

Introducing Super Fog Burzt: A Game Changer in Edibles Mfused has taken the edible cannabis industry by storm with the introduction of Super Fog Burzt, a fast-acting lemonade that is set to redefine how consumers experience cannabis edibles. Unlike traditional edibles, which can take time to kick in, Super Fog Burzt offers a quick-acting solution that allows users to...

Continue Reading
Target Hospitality Updates Bylaws for Enhanced Governance and Clarity

Updated Category News Views 89

Target Hospitality's Bylaw Amendments and Their Implications Target Hospitality Corp. (NASDAQ: TH), known for providing lodging services to sectors such as energy and construction, has recently undertaken important amendments to its bylaws, aiming to strengthen governance and improve transparency for its stockholders. This proactive step was revealed in a recent SEC...

Continue Reading
ImmunOs Therapeutics Secures Funding to Advance Cancer Trials

Updated Category News Views 140

Recent Funding Boost for ImmunOs Therapeutics AG ImmunOs Therapeutics AG, an innovative biopharmaceutical company with its own immune system modulating HLA-based technology, has successfully closed a Series C financing round, raising $11 million. This funding will help advance the development of cutting-edge cancer therapies and strengthen relationships with its...

Continue Reading
Goldman Sachs Promotes Leadership in Banking Division Amid Shares Decline

Updated Category News Views 241

Goldman Sachs Adjusts Leadership in Banking & Markets Goldman Sachs is making notable changes within its banking and markets division, ushering in a new era of leadership as part of its latest strategic move. This adjustment reflects the firm’s commitment to evolve its managerial structure and improve operational efficiency. New Leadership Appointments As reported...

Continue Reading
Otis Worldwide Corporation CEO to Engage at Major Conference

Updated Category News Views 168

Otis Worldwide Corporation CEO to Join Industry Leaders at Key Conference Otis Worldwide Corporation (NYSE: OTIS) is set to have its esteemed Chair, CEO, and President, Judy Marks, present at an influential conference hosted by Morgan Stanley. Well-known for her leadership and innovative vision, Judy Marks will participate in a fireside chat at the annual Laguna...

Continue Reading